Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?
Authors:
Open Access
- 28 October 2021
- journal article
- editorial
- Published by Elsevier in The Lancet Microbe
- Vol. 2 (12) , e648-e649
Abstract
No abstract availableFunding Information
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- US Department of Veterans Affairs
- Burroughs Wellcome Fund
- Cystic Fibrosis Foundation
- National Institutes of Health Office of the Director
This publication has 10 references indexed in Scilit:
- New Perspectives on Antimicrobial Agents: CefiderocolAntimicrobial Agents and Chemotherapy, 2021
- Treatment of patients with serious infections due to carbapenem‐resistant Acinetobacter baumannii: How viable are the current options?Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2021
- Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogensThe Lancet Infectious Diseases, 2021
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trialThe Lancet Infectious Diseases, 2021
- Cefiderocol: the Trojan horse has arrived but will Troy fall?The Lancet Infectious Diseases, 2021
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialThe Lancet Infectious Diseases, 2021
- US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Clinical Infectious Diseases, 2020
- Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?Antimicrobial Agents and Chemotherapy, 2020
- Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infectionNature Microbiology, 2019
- In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016Antimicrobial Agents and Chemotherapy, 2018